Stockscreener 앱 받기
480.77
0.08%
0.44
전일 마감가:
$480.33
열려 있는:
$481.36
하루 거래량:
169.89K
Relative Volume:
0.11
시가총액:
$123.34B
수익:
$11.02B
순이익/손실:
$-535.60M
주가수익비율:
-218.53
EPS:
-2.2
순현금흐름:
$-978.00M
1주 성능:
+4.73%
1개월 성능:
+12.34%
6개월 성능:
-1.11%
1년 성능:
+14.55%
1일 변동 폭
$479.85
$486.24
1주일 범위
$451.99
$486.24
52주 변동 폭
$377.85
$519.88
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
481.15 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.27 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.11 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Handelsbanken Fonder AB Sells 115,479 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now - The Motley Fool
CIBC Asset Management Inc Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Ieq Capital LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Davidson Investment Advisors Buys 12,631 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lifted by Baillie Gifford & Co. - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.com to "Hold" - MarketBeat
Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 244 Shares of Stock - MarketBeat
Analyst Expectations For Vertex Pharmaceuticals's Future - Benzinga
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink? - Nasdaq
RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $408 From $407, Maintains Sector Perform Rating - Marketscreener.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Cumberland Partners Ltd - MarketBeat
Private Wealth Partners LLC Trims Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Boosted by Convergence Investment Partners LLC - MarketBeat
Kestra Investment Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
Vertex Pharmaceuticals EVP Biller sells shares worth $754,034 - Investing.com India
Truist Financial Corp Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
TKG Advisors LLC Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
2025’s Biggest New Launches - News & Insights
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Mcrae Capital Management Inc. - MarketBeat
New York State Common Retirement Fund Purchases 2,855 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Blue Trust Inc. Reduces Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
3,750 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by ABC Arbitrage SA - MarketBeat
Vertex to Participate in Upcoming March Investor Conferences - Yahoo Finance
Kentucky Retirement Systems Insurance Trust Fund Acquires 636 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Braun Stacey Associates Inc. Sells 6,047 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Pain biotech Latigo eyes up to $150M raise following Vertex’s landmark FDA nod - Endpoints News
Venturi Wealth Management LLC Acquires 3,580 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Raised by Sanctuary Advisors LLC - MarketBeat
Vertex grew headcount 13% for the second straight year - The Business Journals
Principal Financial Group Inc. Sells 13,827 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Principal Securities Inc. Has $2.20 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Csenge Advisory Group Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Kessler Investment Group LLC Has $553,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Banque Pictet & Cie SA Has $4.85 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Chevy Chase Trust Holdings LLC Sells 2,160 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Compagnie Lombard Odier SCmA Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Bogart Wealth LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Empowered Funds LLC Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Vontobel Holding Ltd. - MarketBeat
Ingalls & Snyder LLC Has $1.20 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Van ECK Associates Corp Acquires 7,841 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
AlphaCentric Advisors LLC Acquires New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Americana Partners LLC - MarketBeat
What is Leerink Partnrs' Estimate for VRTX Q1 Earnings? - MarketBeat
New York State Teachers Retirement System Sells 10,729 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Strategic Financial Concepts LLC Makes New $8.11 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
G&S Capital LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Rhumbline Advisers - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
0.05%
자본화:
|
볼륨(24시간):